Johnson & Johnson Weighs $20 Billion Sale of Its Orthopedics Unit to Apollo
J&J is in talks to sell DePuy Synthes, its $9.3B hip-and-knee unit, to Apollo for about $20B. A deal could close in weeks—or J&J may spin it off.
/ 5 items
#KVUE↓
Kimberly-Clark to Acquire Kenvue in $48.7 Billion Deal
Kimberly-Clark (KMB) announces acquisition of Kenvue (KVUE) for $48.7 billion, creating a global health and wellness powerhouse with 10 billion-dollar brands serving consumers worldwide.
Johnson & Johnson Spins Off DePuy Synthes Amid Pricing Pressure and Strategic Focus on High-Growth Markets
J&J is spinning off its slower-growing $9.2B DePuy Synthes joint replacement business to focus on high-profit drugs and handle US price demands.
Starboard Value Builds Stake in Keurig Dr Pepper Following Controversial Acquisition Deal
Activist investor Starboard Value takes position in Keurig Dr Pepper after its €15.7B JDE Peet's acquisition announcement triggered 25% stock decline and investor concerns.
Trump Administration Links Tylenol to Autism Risk
Trump officials will warn pregnant women that Tylenol (acetaminophen) may cause autism and suggest a drug called leucovorin for treatment. Tylenol's maker and many doctors reject this claim, citing over a decade of research showing no credible link.